SCHEMBL15524670

SCHEMBL15524670

CCC(CON1C(=O)c2ccccc2C1=O)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 6/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ATM Q13315 2/20 0.37
HPGD P15428 2/20 0.37
CYP1A2 P05177 3/20 0.37
MAPT P10636 3/20 0.37
CYP2C9 P11712 1/20 0.37
RECQL P46063 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
HTT P42858 1/20 0.35
KDM4E B2RXH2 2/20 0.34
F2 P00734 1/20 0.34
VDR P11473 1/20 0.34
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15524669 1.00 POLB (0.41) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL3971334 0.84 POLB (0.43) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL1581269 0.84 POLB (0.43) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL1581270 0.84 POLB (0.43) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL15063103 0.75 GAA (0.45) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL15063102 0.75 GAA (0.45) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL4711928 0.74 ALDH1A1 (0.47) POLBGAAALDH1A1KMT2AHPGD
SCHEMBL20346803 0.74 GAA (0.37) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL9544542 0.73 GAA (0.58) POLBSMN1; SMN2GAAALDH1A1MEN1
SCHEMBL16323016 0.72 GAA (0.45) POLBSMN1; SMN2GAAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635587-B1 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS CENTAURUS BIOPHARMA CO LTD (CN) 2017-02-15 EP disclosed
US-9540396-B2 6-arylamino pyridone carboxamide as MEK inhibitors CENTAURUS BIOPHARMA CO., LTD. (CN) 2017-01-10 US disclosed
US-20140080804-A1 NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS CENTAURUS BIOPHARMA CO., LTD. (CN) 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080804-A1 NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS MAP3K6, MAP3K1, MAP3K21 POLB 789/4885SMN1; SMN2 2701/4885GAA 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.